Medical buyers can move between CMEF and ICMD without changing venue, yet the two halls answer different questions. One presents finished medical technology and clinical solutions; the other moves upstream into device design, materials, components, processing and manufacturing support. The combination is most valuable for buyers responsible for both the finished device and its manufacturing inputs.
When the combination makes sense
Attend CMEF Beijing 2026 and ICMD together when the mission includes OEM/ODM development, private label, component sourcing, supplier localisation or manufacturing transfer. Keep the visit centred on CMEF when purchasing finished equipment for a hospital, clinic or distribution portfolio and no product-development decision is involved.
The two events are a genuine same-trip combination because they run from 21 to 24 October 2026 at the same Beijing venue. They are not substitutes: ICMD cannot replace the finished-device and clinical market view at CMEF, while CMEF cannot provide the same upstream manufacturing depth.
What each exhibition contributes
China International Medical Equipment Fair (CMEF) 2026 covers finished medical technology across medical imaging, diagnostics, electronics, optics, operating-room equipment, consumables, orthopaedics, rehabilitation, robotics and related categories.
ICMD 2026 focuses on the design and manufacturing chain: materials, components, sensors, electronics, precision processing, moulds, production equipment, packaging and supporting services. Its value is greatest when a team needs to understand what sits behind the finished product.
Pharmaceutical or consumer-health events may share the broad healthcare label, but they do not become comparable medical-device sourcing shows. They belong in the trip when the team also has a separate pharmaceutical or consumer-health buying brief.
Who should combine the two halls
The combined route fits medical-device brands seeking manufacturing partners; engineering teams comparing sensors, materials, boards or tooling; procurement teams developing a second source; and distributors with a defined private-label brief plus regulatory resources.
A hospital comparing standard equipment should instead preserve time for clinical workflow, training, service response, installed-base references and lifecycle support. An upstream component buyer may do the reverse: spend most time at ICMD and use CMEF to understand how candidate technologies appear in complete systems.
Follow one product question across both shows
Use one connected contact list for both halls. Start at CMEF with the intended use, user workflow and finished-device requirements. Identify the performance, supply-chain or design questions that remain open, then take those specific questions into ICMD.
For an electronic device, that might mean sensors, PCB assembly, power architecture, enclosure tooling or test fixtures. For a sterile disposable, it could mean material grade, forming, clean manufacturing, packaging and sterilisation responsibility. For rehabilitation equipment, it may be motors, controls, mechanical assemblies and software interfaces.
Return to the finished-device candidate with the upstream findings. This is how a same-venue combination creates decision value rather than simply doubling the number of business cards.
Establish the regulatory responsibility map
Before discussing factory visits, identify the legal manufacturer, registration holder, design owner, contract manufacturer and critical suppliers. Ask who maintains the technical file, approves changes, investigates complaints and supports destination-market registration.
An upstream supplier may provide an important material or module without carrying responsibility for the finished device’s clinical performance or regulatory compliance. Conversely, a brand shown at CMEF may outsource major production steps. The buyer needs the contractual and documentary chain, not assumptions based on logos.
For private-label or OEM projects, document exactly which party controls intended use, claims, labelling, software, risk management, verification, validation and post-market activities. Qualified regulatory specialists should review destination-market requirements.
Evidence to request after the show
For finished devices, request product identification, intended use, applicable registration information, performance evidence, service arrangement, training, accessories, consumables, software version and change policy. For manufacturing partners, add facility scope, quality-system documentation, process capability, validation responsibility, traceability and critical subcontractors.
For components and materials, clarify specification revision, incoming and outgoing controls, lot traceability, change notification, shelf life where relevant and evidence supporting the intended application. A sample on a stand does not establish biocompatibility, electrical safety, cybersecurity, sterilisation validity or production consistency.
The organiser’s exhibitor search is a planning source, not an approval list.
A two-day working route
Day one morning — CMEF: compare complete products and define the shortlist. Record unresolved design, compliance and supply questions.
Day one afternoon — ICMD: investigate only the upstream issues linked to those products. Schedule follow-up with technical staff rather than collecting general catalogues.
Day two morning — return meetings: challenge finished-device candidates with the responsibility and evidence gaps identified upstream.
Day two afternoon — closure: agree a document index, named owners and dates. Decide whether the next step is a regulatory review, technical workshop, remote facility assessment or targeted factory visit.
Additional show days can be used for other product families, but each should repeat this closed loop.
When a factory visit is justified
A factory visit is most useful when the exact manufacturing site and the question it must answer are known. Relevant checks may include production ownership, clean-area controls where applicable, process validation, test equipment, calibration, traceability, nonconformity handling, software release control and change management.
Do not use a factory tour as a substitute for missing regulatory evidence. If the open issue is clinical performance, registration status or cybersecurity documentation, the correct next step is expert document review. Xentra can coordinate bilingual meetings and visits, but does not replace qualified regulatory, clinical or certification judgement.
Official sources
Checked and updated: July 24, 2026.